Review
Dermatology
B. L. Stuart, L. Howells, R. L. Pattinson, J. R. Chalmers, D. Grindlay, N. K. Rogers, E. Grinich, T. Pawlitschek, E. L. Simpson, K. S. Thomas
Summary: The HOME initiative established a core outcome set for eczema clinical trials, including the domain for patient-reported eczema control. A review of validated instruments identified two tools, RECAP and ADCT, as suitable patient-reported outcome instruments for measuring atopic eczema control.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Julius Garcia Gatmaitan, Ji Hyun Lee
Summary: Atopic dermatitis is a complex condition with various factors affecting its treatment and management. In addition to conventional therapies, new drugs targeting specific molecular pathways in atopic dermatitis are being developed to address its complex pathophysiology. The efficacy of these drugs depends on factors such as genotype, environmental triggers, microbiome-derived signals, and immune responses. This review highlights the challenges and recent pharmacological developments in atopic dermatitis, aiming for a more personalized therapeutic approach.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Aihua Li, Minlu Zhang, Yating Yang, Joshua Zhang, Xiaoping Xie, Xiaoxian Li, Hui Zhang
Summary: This study reviewed the quality of recently developed patient-reported outcome (PRO) tools for disease severity and quality of life (QOL) in atopic dermatitis (AD) patients, and recommended a few reliable and valid tools. However, no fully validated Chinese PRO tools were found.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Article
Immunology
Pei-Yun Shih, Chia-Jung Li, Su-Boon Yong
Summary: Atopic dermatitis is a chronic inflammatory skin disease characterized by immune function imbalance and impaired epidermal barrier function. The JAK/STAT signaling pathway plays a critical role in its pathogenesis, and JAK inhibitors offer a novel therapeutic approach.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Yung-Sen Chang, Chih-Chen Tsai, Pang-Yan Yang, Chih-Yu Tang, Bor-Luen Chiang
Summary: Oral melatonin supplement has been shown to improve dermatitis severity in children with AD. This study investigated the mechanism and immunomodulatory effect of topical melatonin treatment in mice and cell models of AD. The results suggest that melatonin may have a direct immunomodulatory effect on AD and could be a potential treatment for patients with AD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biology
Laura Linares-Gonzalez, Ignacio Lozano-Lozano, Luis Gutierrez-Rojas, Mario Lozano-Lozano, Teresa Rodenas-Herranz, Ricardo Ruiz-Villaverde
Summary: Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus as the main symptom, affecting all age ranges. While many diseases have been associated with AD, the causal relationship between AD and psychological impairment is still unclear, and research on sexual dysfunction in AD is limited.
Article
Allergy
Haengdueng Jeong, Nakyum Lee, Chanyang Uhm, Kyungrae Cho, Heeju Oh, Yeseul Oh, KeLun Zhang, Hye Li Kim, James R. Goldenring, Kyung-Min Lim, Chang Ook Park, Ki Taek Nam
Summary: Rab-25 plays an important role in maintaining skin barrier function and keratinization in atopic dermatitis (AD).
Article
Allergy
Angeline S. L. Tay, Chenhao Li, Tannistha Nandi, Kern Rei Chng, Anand Kumar Andiappan, Vijaya Saradhi Mettu, Camille de Cevins, Aarthi Ravikrishnan, Charles-Antoine Dutertre, X. F. Colin C. Wong, Amanda Hui Qi Ng, Sri Anusha Matta, Florent Ginhoux, Olaf Rotzschke, Fook Tim Chew, Mark B. Y. Tang, Yik Weng Yew, Niranjan Nagarajan, John E. A. Common
Summary: Different microbial profiles on AD skin were identified, with dermotype B showing reduced microbial richness, depletion of certain species, individual-specific outlier abundance of Staphylococcus species, and enrichment in metabolic pathways and virulence genes. These microbial configurations were associated with more severe itching, frequent flares, and increased disease severity in patients.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Review
Allergy
Hywel C. Williams, Jochen Schmitt, Kim S. Thomas, Phyllis Spuls, Eric L. Simpson, Christian J. Apfelbacher, Joanne R. Chalmers, Masutaka Furue, Norito Katoh, Louise A. A. Gerbens, Yael A. Leshem, Laura Howells, Jasvinder A. Singh, Maarten Boers
Summary: Core outcome sets are crucial in atopic dermatitis research, providing a standardized approach to measuring outcomes and improving clinical practice.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Psychiatry
C. Jameson, K. A. Boulton, N. Silove, A. J. Guastella
Summary: Growing evidence suggests that genetic, neurological, and environmental factors contribute to the development of autism spectrum disorder (ASD). Interestingly, children with ASD often have skin disorders, possibly due to the shared embryonic origin of skin and neural tissue. This study found that atopic disorders, especially comorbid eczema, are associated with increased ASD symptom severity in children.
TRANSLATIONAL PSYCHIATRY
(2022)
Review
Dermatology
Shuying Zhou, Fei Qi, Yue Gong, Jinping Zhang, Binghua Zhu
Summary: This study summarized the biological therapies for atopic dermatitis, including IL-4/IL-13 inhibitors, JAK inhibitors, and anti-IL-13 antibodies. Among them, dupilumab showed significant therapeutic effects in treating AD.
Review
Medicine, General & Internal
Spyridoula Katsarou, Michael Makris, Efstratios Vakirlis, Stamatios Gregoriou
Summary: This systematic review focuses on the role of tight junctions in atopic dermatitis and their potential impact on therapeutic approaches. The findings suggest that dysfunctional tight junctions are closely associated with the pathogenesis and inflammation in atopic dermatitis, and further investigation into their functionality may lead to improved epidermal barrier function in this condition.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Allergy
Doreen Siegels, Annice Heratizadeh, Susanne Abraham, Jonas Binnmyr, Knut Brockow, Alan D. Irvine, Susanne Halken, Charlotte G. Mortz, Carsten Flohr, Peter Schmid-Grendelmeier, Lauri-Ann Van der Poel, Antonella Muraro, Stephan Weidinger, Thomas Werfel, Jochen Schmitt
Summary: This study critically evaluated systemic treatments for moderate-to-severe AD, with the most reliable and safe trial evidence found for the use of dupilumab in adults for up to 1 year. Limited evidence-based conclusions were drawn for other systemic treatments due to methodological restrictions. Therefore, head-to-head trials with novel systemic treatments are needed to clarify the future role of conventional therapies.
Article
Forestry
Luc Guindon, Sylvie Gauthier, Francis Manka, Marc-Andre Parisien, Ellen Whitman, Pierre Bernier, Andre Beaudoin, Philippe Villemaire, Rob Skakun
Summary: This study aims to establish a geospatial database of burn severity for wildland fires in Canada from 1985 to 2015 and evaluate seasonal and annual trends in burn severity. The results show that burn severity tends to be lower in spring fires compared to summer fires, both nationally and regionally across different units.
CANADIAN JOURNAL OF FOREST RESEARCH
(2021)
Review
Immunology
Marissa Ayasse, Adnan Ahmed, Catherine McCullum, Maria L. Espinosa, Amy S. Paller, Jonathan Silverberg
Summary: A systematic review of published studies found no consistent association between any vaccine regimen and the development of atopic dermatitis (AD), regardless of the quality of the studies. No randomized controlled trials were included in the analysis.
